In the past 10 years, a large number of studies have revealed that there were quite sensitive and effective biomarkers that can affect the occurrence and progression of GC, for example, Graziano et al. (2004) found that methylation of the CpG island in the promoter region of the CDH1 gene will lead to a change in CDH1 expression, which may play an important role in the occurrence and progression of diffusive GC, and CDH1 is likely to be one of the therapeutic targets of GC. The gene discussed is CDH1; the disease is gastric cancer.